Hookipa Pharma (HOOK) News Today → “Retirement Secret” Showed 995% Gain Last Time We Shared It (From Stansberry Research) (Ad) Free HOOK Stock Alerts $0.81 -0.04 (-4.73%) (As of 04/25/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineHOOKIPA Pharma Announces Pivotal Phase 2/3 Trial Design for HB-200 in Combination with Pembrolizumabglobenewswire.com - April 25 at 7:01 AMBuy Rating Affirmed for Hookipa Pharma Amidst Promising Pipeline and Strategic Advancementsmarkets.businessinsider.com - April 24 at 9:08 PMHOOKIPA Pharma Announces FDA Clearance of its Investigational New Drug Application for HB-700 for the Treatment of KRAS-Mutated Cancersglobenewswire.com - April 24 at 7:01 AMHOOKIPA Pharma Inc.: HOOKIPA Pharma Announces Grant of Inducement Award Under Nasdaq Listing Rule 5635(c)(4)finanznachrichten.de - April 17 at 10:29 AMHOOKIPA Pharma Announces Grant of Inducement Award Under Nasdaq Listing Rule 5635(c)(4)finance.yahoo.com - April 16 at 6:51 PMHookipa Pharma Inc (NASDAQ:HOOK) Short Interest Down 5.2% in Marchamericanbankingnews.com - April 16 at 2:30 AMHOOKIPA Pharma to Host Investor Call on HB-200 and Planned Path to Registrationglobenewswire.com - April 10 at 7:01 AMHookipa Pharma Inc (NASDAQ:HOOK) Sees Significant Growth in Short Interestmarketbeat.com - April 1 at 8:36 PMOptimistic Buy Rating for Hookipa Pharma Based on Promising HB-200 Trial Results and Strategic Trial Designmarkets.businessinsider.com - March 27 at 8:50 AMHookipa Pharma Inc (NASDAQ:HOOK) Expected to Post FY2028 Earnings of $0.31 Per Sharemarketbeat.com - March 26 at 8:26 AMHookipa Pharma's (HOOK) "Outperform" Rating Reaffirmed at Royal Bank of Canadamarketbeat.com - March 25 at 12:19 PMHOOKIPA Pharma Inc.: HOOKIPA Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlightsfinanznachrichten.de - March 24 at 5:14 PMTime To Worry? Analysts Just Downgraded Their HOOKIPA Pharma Inc. (NASDAQ:HOOK) Outlookfinance.yahoo.com - March 24 at 9:19 AMHOOKIPA Pharma Stock (NASDAQ:HOOK), Earnings Estimates, EPS, and Revenuebenzinga.com - March 23 at 4:51 AMBuy Rating Affirmed for Hookipa Pharma on Emerging Oncology and Infectious Disease Pipelinesmarkets.businessinsider.com - March 23 at 4:51 AMHOOKIPA Pharma GAAP EPS of -$0.22 misses by $0.02, revenue of $7.41M beats by $2.85Mmsn.com - March 22 at 9:18 AMHOOKIPA Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlightsglobenewswire.com - March 22 at 7:01 AMHOOKIPA Pharma to Participate in Leerink Partners Global Biopharma Conferenceglobenewswire.com - March 6 at 7:01 AMHookipa Pharma (NASDAQ:HOOK) Stock Price Down 4%marketbeat.com - March 1 at 2:20 AMHOOKIPA Pharma Inc HOOKmorningstar.com - February 28 at 7:29 PMHOOKIPA Pharma Stock (NASDAQ:HOOK) Dividends: History, Yield and Datesbenzinga.com - February 22 at 8:00 AMAll You Need to Know About HOOKIPA Pharma Inc. (HOOK) Rating Upgrade to Strong Buyfinance.yahoo.com - February 2 at 2:50 PMMaintaining Buy Rating on Hookipa Pharma Amid Strategic Repositioning and Pipeline Promisemarkets.businessinsider.com - February 1 at 8:55 AMHookipa Pharma Inc (NASDAQ:HOOK) Forecasted to Post FY2024 Earnings of ($0.27) Per Sharemarketbeat.com - February 1 at 6:30 AMHookipa Pharma Inc (HOOK)uk.investing.com - January 31 at 9:43 AMRoyal Bank of Canada Lowers Hookipa Pharma (NASDAQ:HOOK) Price Target to $5.00marketbeat.com - January 30 at 10:23 AMStrategic Focus on Promising HPV+ Cancer Candidate Underpins Buy Rating for Hookipa Pharmamarkets.businessinsider.com - January 29 at 7:39 PMHOOKIPA Pharma To Cut Jobs Following Collaboration Termination By Rochemarkets.businessinsider.com - January 29 at 2:38 PMRoche Walks Away From HOOKIPA Pharma-Partnered KRAS-Focused Cancer Dealmsn.com - January 29 at 2:38 PMHOOKIPA Pharma Shares Fall Premarket as Roche Ends Collaborationmarketwatch.com - January 29 at 9:37 AMHOOKIPA Pharma Inc.: HOOKIPA Pharma Appoints Mark Winderlich as Chief Development Officer to Lead Clinical Research and Development Organizationfinanznachrichten.de - January 16 at 9:02 AMHOOKIPA Pharma Appoints Mark Winderlich as Chief Development Officer to Lead Clinical Research and Development Organizationfinance.yahoo.com - January 16 at 9:02 AMHOOKIPA Pharma Appoints Mark Winderlich as Chief Development Officer to Lead Clinical Research and Development Organizationfinance.yahoo.com - January 16 at 9:02 AMHOOKIPA Pharma Inc.: HOOKIPA Pharma Announces $21.25 Million Equity Investment from Gilead Sciencesfinanznachrichten.de - December 22 at 12:42 PMHOOKIPA Pharma files to sell 15M shares for holdersmsn.com - December 22 at 12:42 PMHOOKIPA Pharma Inc. (HOOK)ca.finance.yahoo.com - December 22 at 7:41 AMHOOKIPA Pharma Shares Soar After Gilead Sciences Investmentmarketwatch.com - December 21 at 10:16 AMHOOKIPA Pharma Announces $21.25 Million Equity Investment from Gilead Sciencesfinance.yahoo.com - December 21 at 10:16 AMWhy Is Hookipa Pharma (HOOK) Stock Up 81% Today?investorplace.com - December 21 at 10:00 AMHOOKIPA Pharma: HB-500 IND Application Gets FDA Clearance To Treat HIVmarkets.businessinsider.com - November 20 at 10:02 AMHOOKIPA Pharma Announces FDA Clearance of its Investigational New Drug Application for HB-500 for the Treatment of Human Immunodeficiency Virusfinance.yahoo.com - November 20 at 10:02 AMPromising Clinical Trials and Strong Financial Performance Bolster Buy Rating for Hookipa Pharmamarkets.businessinsider.com - November 12 at 12:31 AMHOOKIPA Pharma Reports Third Quarter 2023 Financial Results and Recent Business Highlightsmarkets.businessinsider.com - November 10 at 12:24 AMHOOKIPA Pharma Inc.: HOOKIPA Pharma Reports Third Quarter 2023 Financial Results and Recent Business Highlightsfinanznachrichten.de - November 9 at 1:52 PMHOOKIPA Pharma GAAP EPS of -$0.17 beats by $0.03, revenue of $6.87M beats by $2.62Mmsn.com - November 9 at 1:52 PMHOOKIPA Pharma Reports Third Quarter 2023 Financial Results and Recent Business Highlightsfinance.yahoo.com - November 9 at 8:52 AMHOOKIPA Pharma Inc. Reports Increased Revenue and Higher R&D Expenses in Q3 2023finance.yahoo.com - November 9 at 8:52 AMHOOKIPA Pharma Presents Positive Biomarker and Translational Data on HB-200 Monotherapy at Society for Immunotherapy of Cancer 2023finance.yahoo.com - November 3 at 2:23 PMHOOKIPA Pharma to Report Third Quarter 2023 Financial Results and Recent Business Highlights on November 9, 2023finance.yahoo.com - November 2 at 6:56 PMHOOKIPA Pharma Presents Additional Preliminary Phase 2 Data on HB-200 in Combination with Pembrolizumab as First-Line Treatment in Patients with HPV16+ Head and Neck Cancers at European Society for Medical Oncology Congress 2023finance.yahoo.com - October 22 at 8:19 AM Get Hookipa Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for HOOK and its competitors with MarketBeat's FREE daily newsletter. Email Address “Retirement Secret” Showed 995% Gain Last Time We Shared It (Ad)Central Banks Buying Gold in Record Numbers Most folks have completely missed the fact that the world's Central Banks have been quietly gobbling up as much gold as they can… Stacking it in their locked vaults on pallets in record numbers. Find out why right here (and see what you can do to get in too with just a few dollars). HOOK Media Mentions By Week HOOK Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. HOOK News Sentiment▼0.600.40▲Average Medical News Sentiment HOOK News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. HOOK Articles This Week▼31▲HOOK Articles Average Week Get Hookipa Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for HOOK and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: YS Biopharma News Today Spero Therapeutics News Today Affimed News Today Oncolytics Biotech News Today Eton Pharmaceuticals News Today BioXcel Therapeutics News Today Chimerix News Today PMV Pharmaceuticals News Today InflaRx News Today SELLAS Life Sciences Group News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:HOOK) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsYour Money is Not SafeAmerican AlternativeFed launches fourth dollar overhaulStansberry ResearchThe World's First "$20 Trillion Drug?"Behind the MarketsEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest MetalsI’m afraid WWIII is a very real possibility Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Hookipa Pharma Inc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
